Andrea Schiefer
Overview
Explore the profile of Andrea Schiefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in
Balansky J, Pfarr K, Szekat C, Kehraus S, Aden T, Grosse M, et al.
Antibiotics (Basel)
. 2022 Jul;
11(7).
PMID: 35884174
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined...
12.
Krome A, Becker T, Kehraus S, Schiefer A, Gutschow M, Chaverra-Munoz L, et al.
Nat Prod Rep
. 2022 Jun;
39(9):1705-1720.
PMID: 35730490
Covering: August 1984 up to January 2022Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as...
13.
Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L, et al.
Nat Rev Chem
. 2021 Aug;
5(10):726-749.
PMID: 34426795
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in...
14.
Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections
Schiefer A, Hubner M, Krome A, Lammer C, Ehrens A, Aden T, et al.
PLoS Negl Trop Dis
. 2020 Dec;
14(12):e0008930.
PMID: 33284808
Current efforts to eliminate the neglected tropical diseases onchocerciasis and lymphatic filariasis, caused by the filarial nematodes Onchocerca volvulus and Wuchereria bancrofti or Brugia spp., respectively, are hampered by lack...
15.
Krome A, Becker T, Kehraus S, Schiefer A, Steinebach C, Aden T, et al.
Pharmaceutics
. 2020 Nov;
12(11).
PMID: 33217948
Novel-antibiotics are urgently needed to combat an increase in morbidity and mortality due to resistant bacteria. The preclinical candidate corallopyronin A (CorA) is a potent antibiotic against Gram-positive and some...
16.
Elaborations on Corallopyronin A as a Novel Treatment Strategy Against Genital Chlamydial Infections
Loeper N, Graspeuntner S, Ledig S, Kaufhold I, Hoellen F, Schiefer A, et al.
Front Microbiol
. 2019 May;
10:943.
PMID: 31134007
Ascending infection causes functional damage to the fallopian tubes, which may lead to ectopic pregnancy and infertility in women. Treatment failures using the standard regimens of doxycycline and azithromycin have...
17.
Bouhired S, Rupp O, Blom J, Schaberle T, Schiefer A, Kehraus S, et al.
Microbiol Resour Announc
. 2019 Apr;
8(17).
PMID: 31023790
Myxobacteria are a source of unique metabolites, including corallopyronin A (CorA), a promising antibiotic agent in preclinical development for the treatment of filariasis. To investigate the production of CorA on...
18.
Mukherjee S, Joardar N, Mondal S, Schiefer A, Hoerauf A, Pfarr K, et al.
Sci Rep
. 2018 Aug;
8(1):12073.
PMID: 30104608
Search of potent antifilarial drugs has been a major thrust area in tropical medicine research over the decades. Herein, we report 4,7-dimethyl-3,4,7,8-tetrahydro-3λ-[1,2]thiazino[4,3-f]quinoline-3,3,8-trione (8l) as a new class of antifilarial agent...
19.
Shima K, Ledig S, Loeper N, Schiefer A, Pfarr K, Hoerauf A, et al.
Int J Antimicrob Agents
. 2018 Aug;
52(4):523-524.
PMID: 30092271
No abstract available.
20.
Weber J, Schwarz M, Schiefer A, Hametner C, Haubl G, Frohlich J, et al.
European J Org Chem
. 2018 Jun;
2018(20-21):2701-2706.
PMID: 29937688
The synthesis of (2-nitrophenyl)acetyl (NPAc)-protected glucosyl donors is described that were designed for the neighboring-group assisted glucosylation of base-labile natural products also being sensitive to hydrogenolysis. Glycosylation conditions were optimized...